Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

High EphA2 protein expression in renal cell carcinoma is associated with a poor disease outcome.

Xu J, Zhang J, Cui L, Zhang H, Zhang S, Bai Y.

Oncol Lett. 2014 Aug;8(2):687-692.

2.

Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma.

Herrem CJ, Tatsumi T, Olson KS, Shirai K, Finke JH, Bukowski RM, Zhou M, Richmond AL, Derweesh I, Kinch MS, Storkus WJ.

Clin Cancer Res. 2005 Jan 1;11(1):226-31.

3.

The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas.

Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM, Suo Z.

Gynecol Oncol. 2005 Nov;99(2):278-86.

PMID:
16061279
4.

Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.

Ishikawa M, Miyahara R, Sonobe M, Horiuchi M, Mennju T, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N, Huang CL, Date H.

Lung Cancer. 2012 Jun;76(3):431-8. doi: 10.1016/j.lungcan.2011.12.004.

PMID:
22236865
5.

Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma.

Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E, Storkus WJ.

Cancer Res. 2003 Aug 1;63(15):4481-9.

6.

EphA2 expression is associated with aggressive features in ovarian carcinoma.

Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK.

Clin Cancer Res. 2004 Aug 1;10(15):5145-50.

7.

Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis.

Holm R, Knopp S, Suo Z, Tropè C, Nesland JM.

J Clin Pathol. 2007 Oct;60(10):1086-91.

8.

Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma.

Wu D, Suo Z, Kristensen GB, Li S, Troen G, Holm R, Nesland JM.

Gynecol Oncol. 2004 Aug;94(2):312-9.

PMID:
15297167
9.

Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.

Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, Wu L, Dhariwal J, Mohammed SI.

Clin Cancer Res. 2006 Jan 15;12(2):353-60.

10.

[Overexpression of the receptor tyrosine kinase EphA2 in choroidal melanoma: correlation with vesculogenic mimicry and prognosis].

Chen LX, Sun BC, Li XR, He YJ, Song GX.

Zhonghua Yan Ke Za Zhi. 2012 Nov;48(11):985-90. Chinese.

PMID:
23302271
11.

Overexpression of the EphA2 tyrosine kinase in prostate cancer.

Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS.

Prostate. 1999 Dec 1;41(4):275-80.

PMID:
10544301
12.

Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.

Merritt WM, Thaker PH, Landen CN Jr, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK.

Cancer Biol Ther. 2006 Oct;5(10):1357-60.

PMID:
16969087
13.

Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma.

Li X, Wang L, Gu JW, Li B, Liu WP, Wang YG, Zhang X, Zhen HN, Fei Z.

Tumour Biol. 2010 Oct;31(5):477-88. doi: 10.1007/s13277-010-0060-6.

PMID:
20571968
14.

[Correlation of EphA2 protein expression with clinicopathological characteristics and prognosis in laryngeal squamous cell carcinoma].

Liu Y, Zhang X, Qiu YZ, Huang DH, Zhou XJ, Tan PQ, Cai GM, Dai YZ, Yu CY, Xiao JY, Tian YQ.

Zhonghua Zhong Liu Za Zhi. 2011 Mar;33(3):197-201. Chinese.

PMID:
21575519
15.

Upregulation of EphA2 during in vivo and in vitro renal ischemia-reperfusion injury: role of Src kinases.

Baldwin C, Chen ZW, Bedirian A, Yokota N, Nasr SH, Rabb H, Lemay S.

Am J Physiol Renal Physiol. 2006 Nov;291(5):F960-71.

16.

Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma.

Xu F, Zhong W, Li J, Shanshen Z, Cui J, Nesland JM, Suo Z.

Anticancer Res. 2005 Jul-Aug;25(4):2943-50.

17.

[Expression of EphA2 and EphrinA1 in human renal cell carcinoma and its relationship with angiogenesis].

Xu JS, Zhang JX, Geng TH, Wang YF, Wang XL, Zuo LF.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):438-41. Chinese.

PMID:
19950554
18.

EphA2 as a promoter of melanoma tumorigenicity.

Margaryan NV, Strizzi L, Abbott DE, Seftor EA, Rao MS, Hendrix MJ, Hess AR.

Cancer Biol Ther. 2009 Feb;8(3):279-88.

19.

Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis.

Holm R, de Putte GV, Suo Z, Lie AK, Kristensen GB.

Int J Med Sci. 2008 Jun 5;5(3):121-6.

20.

Involvement of EphA2 in head and neck squamous cell carcinoma: mRNA expression, loss of heterozygosity and immunohistochemical studies.

Rivera RS, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K, Beder LB, Pehlivan D, Yamanaka N, Shimizu K, Nagai N.

Oncol Rep. 2008 May;19(5):1079-84.

PMID:
18425361
Items per page

Supplemental Content

Support Center